The Mt. Sinai study could open the door to future therapies for Alzheimer’s, amyotrophic lateral sclerosis, brain cancer, and ...

Scientists at the Icahn School of Medicine at Mount Sinai have developed a lipid nanoparticle system capable of delivering ...

Scientists have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that has long been limited by the protective nature ...

Scientists have developed a lipid nanoparticle system that enables mRNA to cross the blood-brain barrier, a long-standing challenge in n.

Scientists at the Icahn School of Medicine at Mount Sinai have developed a lipid nanoparticle system capable of delivering ...

The Swedish biotech behind a groundbreaking Alzheimer’s treatment is in talks with partners for its new technology that allows drugs to cross the notoriously tricky blood-brain barrier.

Scientists explore how the immune and nervous systems constantly communicate, influencing brain diseases, behavior, and ...

Alzheimer’s disease (AD) — a neurodegenerative disorder — comes with a significant socioeconomic burden. Recent studies have ...

A newly identified part of a brain circuit mixes sensory information, memories, and emotions to tell whether things are familiar or new, and important or just 'background noise.' ...

Using portable EEGs, researchers found that when groups of people watch the same health promotion videos, their brain activity syncs up, indicating that the message has gone beyond being seen and ...

Researchers investigated cerebral small vessel disease, a precursor to dementia, by analyzing data from thousands of ...

Rasagiline is rapidly absorbed by the gastrointestinal tract and readily crosses the blood-brain barrier. The optimal therapeutic dosage is 0.5-1 mg administered orally once daily. Rasagiline ...